약물전달용 나노플랫폼은 약물의 안정성 , 생체이용률 , 표적 전달성 및 방출 제어성을 향상시키기 위한 핵심 제형 기 술로 발전해 왔다. 본 총설에서는 차세대 약물전달용 나노플랫폼으로서 나노구조 지질 운반체 (nanostructured lipid carriers, NLC), 금속 -유기 골격체 (metal-organic frameworks, MOF) 및 외막소포체 (outer membrane vesicles, OMV)의 구조적 특성 , 약물 적재 및 방출 기전 , 제조기술 , 품질평가 지표 및 산업화 고려사항을 검토하였다 . NLC는 지질 매트 릭스를 기반으로 난용성 약물 적재와 제조공정 확장성에 장점을 가지며 , MOF는 다공성 골격 구조를 통해 고용량 적 재와 자극 반응성 방출이 가능하다 . OMV는 생물유래 막 구조를 기반으로 치료용 전달물질 (cargo)의 운반과 면역조절 기능을 동시에 나타낼 수 있으나 , 내독성 및 배치 간 변동성 관리가 중요하다 . 이들 플랫폼의 실용화를 위해서는  QbD와 PAT를 기반으로 제조공정 중 품질 변동을 예측 ·관리하고 , 장기 안정성 평가와 규제 대응을 연계한 통합적 품질관리 체 계를 구축해야 한다 .

Drug delivery nanoplatforms have been developed to improve drug stability, bioavailability, target delivery, and controlled release. This review summarizes the structural features, drug loading and release mechanisms, manufacturing technologies, quality attributes, and industrial considerations of nanostructured lipid carriers (NLCs), metal-organic frameworks (MOFs), and outer membrane vesicles (OMVs) as next-generation drug delivery nanoplatforms. NLCs provide advantages in loading poorly water-soluble drugs and scalable formulation development based on lipid matrices. MOFs enable high- capacity drug loading and stimuli-responsive release through tunable porous frameworks. OMVs offer bio-derived membrane functions for cargo delivery and immunomodulation, although endotoxin control and batch-to-batch variability remain critical issues. Accordingly, the industrial translation of these platforms requires a process-centered quality-control strategy that uses QbD and PAT to predict and manage manufacturing variability while integrating long-term stability and regulatory-oriented safety assessment.

Nanostructured lipid carriers, Metal-organic frameworks, Outer membrane vesicles, Drug delivery, Quality by design

1. Fahmy, T. M., Fong, P. M., Goyal, A. and Saltzman, W. M., “Targeted for Drug Delivery,” Mater. Today, 8(8), 18-26(2005).
2. Bangham, A. D., Standish, M. M. and Watkins, J. C., “Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholip- ids,” J. Mol. Biol., 13(1), 238-252(1965).
3. Scherphof, G. L., Dijkstra, J., Spanjer, H. H., Derksen, J. T. P. and Roerdink, F. H., “Uptake and Intracellular Processing of Targeted and Nontargeted Liposomes by Rat Kupffer Cells in Vivo and in Vitro,” Ann. N. Y. Acad. Sci., 446(1), 368-384(1985).
4. Singh, R. P. and Ramarao, P., “Accumulated Polymer Degradation Products as Effector Molecules in Cytotoxicity of Polymeric Nanoparticles,” Toxicol. Sci., 136(1), 131-143(2013).
5. zur Mühlen, A., Schwarz, C. and Mehnert, W., “Solid Lipid Nanoparti- cles for Controlled Drug Delivery-Drug Release and Release Mechanism,” Eur. J. Pharm. Biopharm., 45(2), 149-155(1998).
6. Woo, Y., Yoon, J., Seo, Y., Han, Y., Yoo, H. Y., Sohn, H., Lee, M. H. and Lee, T., “Structure-Centered Design of Lipid-Based Nano- carriers to Overcome Biological Barriers,” Mater. Today Bio, 35, 102425(2025).
7. Seo, Y., Lim, H., Park, H., Yu, J., An, J., Yoo, H. Y. and Lee, T., “Recent Progress of Lipid Nanoparticles-Based Lipophilic Drug Delivery: Focus on Surface Modifications,” Pharmaceutics, 15(3), 772(2023).
8. Kang, S., Woo, Y., Seo, Y., Yoo, D., Kwon, D., Park, H., Lee, S. D., Yoo, H. Y. and Lee, T., “A Descriptive Review on the Potential Use of Diatom Biosilica as a Powerful Functional Biomaterial: A Natural Drug Delivery System,” Pharmaceutics, 16(9), 1171 (2024).
9. Lee, S. W., Choi, Y., Kim, Y. H., Ham, J. E., Kailasa, S. K. and Park, T. J., “Fabrication of Protein-Inorganic Biohybrid as an Imageable Drug Delivery System Comprising Transferrin, Green Fluorescent Protein, and Copper Phosphate,” Biotechnol. Bioproc. Eng., 30(1), 70-79(2025).
10. Kim, J. H., Kwak, J. H., Choi, H. J., Lee, D., Park, J. H., Kim, O. H. and Kim, S. J., “Enhanced Drug Delivery in Cancer Therapy: Role of TMPRSS4 Protease in Liposomal Engineering,” Bio-technol. Bioproc. Eng., 30(2), 287-298(2025).
11. Kang, H. J., Min, J., Ravichandran, V., Truong, H. Q., Tram, L. T. H., Kim, B. C. and Shim, M. S., “Bioreducible Polysorbate-Based Micelles Encapsulating Mitochondria-Targeting Sonosensitizers
for Efficient Chemo-Sonodynamic Cancer Therapy,” Biotechnol. Bioproc. Eng., 30(4), 642-651(2025).
12. Park, J. S. and Park, K., “In Vivo Therapeutic Effects of Reactive Oxygen Species (ROS)-Scavenging Nanotherapeutics on Dextran Sulphate Sodium-Induced Acute Colitis Model,” Biotechnol. Bio- proc. Eng., 30(5), 794-805(2025).
13. Lee, A., Lee, J. H., So, C., Kim, I. G. and Mok, H., “Exosome- Immobilized Porous Microspheres for Efficiently Combined and Prolonged Cancer Treatment,” Biotechnol. Bioproc. Eng., 29(5), 863-876(2024).
14. Yoon, I. S., Nam, H. J. and Hong, C. A., “Y-Shaped Oligonucleotides:
A Promising Platform for Enhanced Therapy with siRNA and CpG Oligodeoxyribonucleotides,” Biotechnol. Bioproc. Eng., 29(4), 625- 635(2024).
15. Kim, J., Choi, Y., Park, J., Lee, H. Y. and Choi, J., “Peptides Conju- gation on Biomaterials: Chemical Conjugation Approaches and Their Promoted Multifunction for Biomedical Applications,” Biotechnol. Bioproc. Eng., 29(3), 427-439(2024).
16. Kim, M., Kim, D., Jang, H. and Park, J. H., “Harnessing Balloon Flower Root-Derived Nanovesicles to Mitigate Hyperglycemia- Induced Cellular Senescence,” Biotechnol. Bioproc. Eng., 30(3), 534-546(2025).
17. Haider, M., Abdin, S. M., Kamal, L. and Orive, G., “Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review,” Pharmaceutics, 12(3), 288(2020).
18. Horcajada, P., Serre, C., Vallet-Regí, M., Sebban, M., Taulelle, F. and Férey, G., “Metal-Organic Frameworks as Efficient Materials for Drug Delivery,” Angew. Chem. Int. Ed., 45(36), 5974-5978(2006).
19. Ellis, T. N., Leiman, S. A. and Kuehn, M. J., “Naturally Produced Outer Membrane Vesicles from Pseudomonas aeruginosa Elicit
a Potent Innate Immune Response via Combined Sensing of Both Lipopolysaccharide and Protein Components,” Infect. Immun., 78(9), 3822-3831(2010).
20. He, H., Liu, L., Morin, E. E., Liu, M. and Schwendeman, A., “Sur- vey of Clinical Translation of Cancer Nanomedicines: Lessons Learned from Successes and Failures,” Acc. Chem. Res., 52(9), 2445-2461(2019).
21. Crist, R. M., Grossman, J. H., Patri, A. K., Stern, S. T., Dobrovol- skaia, M. A., Clogston, J. D., McNeil, S. E. and Simberg, D., “Com- mon Pitfalls in Nanotechnology: Lessons Learned from NCI’s Nanotechnology Characterization Laboratory,” Integr. Biol., 5(1), 66-73(2013).
22. Choi, H., Seo, H. and Yoon, H., “Fabrication Methods of Micronee- dles with Polymeric Materials,” Korean J. Chem. Eng., 42(1), 1- 11(2025).
23. Tajik, M., Seyed-Sadjadi, M., Zare, K. and Farhadyar, N., “Prepara- tion, Characterization, and Application of Electrospun BAG/ CMC/β-CD Nanofibers for Flutamide Drug Delivery,” Korean J. Chem. Eng., 41(3), 853-868(2024).
24. Lee, M. H., Lee, S. and Yoo, K. S., “Synthesis of Fe-MOF/COF Hybrid Materials for Methane Adsorption Using Design of Experi- ments,” Korean J. Chem. Eng., 41(2), 435-444(2024).
25. Lapasov, S. D. U., Park, J. H., Win, M. Z., San, T. Z., Oo, W. andYi, K. B., “Comparative Study on Ammonia Adsorption Character- istics of Various Porous Materials and Ammonia Adsorption Effect According to MgCl2 Impregnation,” Korean J. Chem. Eng., 42(2), 257-270(2025).
26. Zhang, J., Wu, F., Xu, L., Wen, R., Zhang, X., Xiong, W., He, B., Jiang, S. and Yi, H., “Synthesis of Cu-Supported ZSM-5/UiO-66 Composite Catalysts for Efficient Degradation of Methylene Blue,” Korean J. Chem. Eng., 42(2), 415-428(2025).
27. Nazir, M. A., Kumar, O. P., Ali, R., Hussain, M. D., Ullah, S., Rauf, A., El-Sherbeeny, A. M., Rehman, A. U. and Shah, S. S. A., “Enhanced Photocatalytic Performance of ZIF-67@ZIF-11 in Binary MOF Systems for Rapid Removal of Persistent Organic Pollutants,” Korean J. Chem. Eng., 42(3), 547-561(2025).
28. Choi, H. L., Yang, H., Woo, J., Mun, J. H. and Bae, T. H., “Upcy- cling PET Waste into High-Performance Metal-Organic Frame- works: Sustainable Synthesis of MIL-53(Al) for Gas Separation and Storage,” Korean J. Chem. Eng., 42(14), 3619-3626(2025).
29. Torchilin, V. P., “Micellar Nanocarriers: Pharmaceutical Perspec- tives,” Pharm. Res., 24(1), 1-16(2007).
30. Kesharwani, P., Jain, K. and Jain, N. K., “Dendrimer as Nanocar- rier for Drug Delivery,” Prog. Polym. Sci., 39(2), 268-307(2014).
31. Baltz, N. and Scherließ, R., “Entrapment Efficiency Methodology for Lipid Nanoparticles: A Literature Review,” OpenNano, 24, 100251(2025).
32. Weng, J., Tong, H. H. Y. and Chow, S. F., “In Vitro Release Study of the Polymeric Drug Nanoparticles: Development and Validation of a Novel Method,” Pharmaceutics, 12(8), 732(2020).
33. International Council for Harmonisation, “Stability Testing of New Drug Substances and Products Q1A(R2),” ICH Harmonised Guideline(2003).
34. U.S. Food and Drug Administration, “Drug Products, Including Biological Products, that Contain Nanomaterials,” Guidance for Industry(2022).
35. Rodríguez-Gómez, F. D., Monferrer, D., Penon, O. and Rivera- Gil, P., “Regulatory Pathways and Guidelines for Nanotechnology- Enabled Health Products: A Comparative Review of EU and US Frameworks,” Front. Med., 12, 1544393(2025).
36. International Council for Harmonisation, “Pharmaceutical Develop- ment Q8(R2),” ICH Harmonised Guideline(2009).
37. Buya, A. B., Mahlangu, P. and Witika, B. A., “From Lab to Industrial Development of Lipid Nanocarriers Using Quality by Design Approach,” Int. J. Pharm. X, 8, 100266(2024).
38. International Council for Harmonisation, “Quality Risk Management Q9(R1),” ICH Harmonised Guideline(2023).
39. International Council for Harmonisation, “Pharmaceutical Quality System Q10,” ICH Harmonised Guideline(2008).
40. U.S. Food and Drug Administration, “PAT: A Framework for Innova- tive Pharmaceutical Development, Manufacturing, and Quality Assurance,” Guidance for Industry(2004).
41. Elmowafy, M. and Al-Sanea, M. M., “Nanostructured Lipid Carri- ers as Drug Delivery Platform: Advances in Formulation and Deliv- ery Strategies,” Saudi Pharm. J., 29(9), 999-1012(2021).
42. Li, Q., Cai, T., Huang, Y., Xia, X., Cole, S. P. C. and Cai, Y., “A Review of the Structure, Preparation, and Application of NLCs, PNPs, and PLNs,” Nanomaterials, 7(6), 122(2017).
43. Saedi, A., Rostamizadeh, K., Parsa, M., Dalali, N. and Ahmadi, N., “Preparation and Characterization of Nanostructured Lipid Carriersas Drug Delivery System: Influence of Liquid Lipid Types on Load- ing and Cytotoxicity,” Chem. Phys. Lipids, 216, 65-72(2018).
44. Javed, S., Mangla, B., Almoshari, Y., Sultan, M. and Ahsan, W., “Nanostructured Lipid Carrier System: A Compendium of Their Formulation Development Approaches, Optimization Strategies by Quality by Design, and Recent Applications in Drug Deliv- ery,” Nanotechnol. Rev., 11(1), 1744-1777(2022).
45. Beloqui, A., Solinís, M. Á., Rodríguez-Gascón, A., Almeida, A. J. and Préat, V., “Nanostructured Lipid Carriers: Promising Drug Delivery Systems for Future Clinics,” Nanomedicine, 12(1), 143- 161(2016).
46. Doktorovova, S., Souto, E. B. and Silva, A. M., “Preclinical Safety of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review,” Eur. J. Pharm. Biopharm., 108, 11-24(2016).
47. Kim, D., Liu, X. and Lah, M. S., “Topology Analysis of Metal-Organic Frameworks Based on Metal-Organic Polyhedra as Secondary or Tertiary Building Units,” Inorg. Chem. Front., 2(5), 336-345(2015).
48. Park, K. S., Ni, Z., Côté, A. P., Choi, J. Y., Huang, R., Uribe-Romo, F. J., Chae, H. K., O’Keeffe, M. and Yaghi, O. M., “Exceptional Chemical and Thermal Stability of Zeolitic Imidazolate Frame- works,” Proc. Natl. Acad. Sci. USA, 103(27), 10186-10191(2006).
49. Furukawa, H., Cordova, K. E., O’Keeffe, M. and Yaghi, O. M., “The Chemistry and Applications of Metal-Organic Frameworks,” Science, 341(6149), 1230444(2013).
50. Eddaoudi, M., Kim, J., Rosi, N. L., Vodak, D., Wachter, J., O’Keeffe, M. and Yaghi, O. M., “Systematic Design of Pore Size and Func- tionality in Isoreticular MOFs and Their Application in Meth- ane Storage,” Science, 295(5554), 469-472(2002).
51. Lin, S. X., Pan, W. L., Niu, R. J., Liu, Y., Chen, J. X., Zhang, W. H., Lang, J. P. and Young, D. J., “Effective Loading of Cisplatin into a Nanoscale UiO-66 Metal-Organic Framework with Preformed Defects,” Dalton Trans., 48(16), 5308-5314(2019).
52. Liang, K., Riccò, R., Doherty, C. M., Styles, M. J., Bell, S. G., Kirby, N., Mudie, S., Haylock, D. N., Hill, A. J., Doonan, C. J. and Falcaro, P., “Biomimetic Mineralization of Metal-Organic Frameworks as Protective Coatings for Biomacromolecules,” Nat. Commun., 6, 7240(2015).
53. Velasquez-Hernandez, M. J., Linares-Moreau, M., Astria, E., Car- raro, F., Alyami, M. Z., Khashab, N. M., Sumby, C. J., Doonan, C. J. and Falcaro, P., “Towards Applications of Bioentities@MOFs in Biomedicine,” Coord. Chem. Rev., 429, 213651(2021).
54. Cai, W., Wang, J., Chu, C., Chen, W., Wu, C. and Liu, G., “Metal- Organic Framework-Based Stimuli-Responsive Systems for Drug Delivery,” Adv. Sci., 6(1), 1801526(2019).
55. Zhou, Z., Vázquez-González, M. and Willner, I., “Stimuli-Responsive Metal-Organic Framework Nanoparticles for Controlled Drug Delivery and Medical Applications,” Chem. Soc. Rev., 50(6), 3541- 3563(2021).
56. Luzuriaga, M. A., Herbert, F. C., Brohlin, O. R., Galindo-Murillo, R. and Gassensmith, J. J., “ZIF-8 Degrades in Cell Media, Serum, and Some-But Not All-Common Laboratory Buffers,” Supramol. Chem., 31(8), 485-490(2019).
57. Mao, A. S. and Mooney, D. J., “Protein Corona: Friend or Foe? Co-Opting Serum Proteins for Nanoparticle Delivery,” Adv. Drug Deliv. Rev., 192, 114635(2022).
58. Rojas, S., Arenas-Vivo, A. and Horcajada, P., “Metal-Organic Frame- works at the Biointerface,” Chem. Soc. Rev., 49(13), 4386-4400(2020).
59. Oh, J. Y., Sim, Y., Yang, G., Park, M. H., Kim, K. and Ryu, J. H., “Surface Functionalization of Metal-Organic Framework Nanoparti- cle for Overcoming Biological Barrier in Cancer Therapy,” Inorg. Chem. Front., 11(11), 3119-3135(2024).
60. Hill, A. K., Sutton, A. D. and Collins, J., “Versatile, High Quality and Scalable Continuous Flow Production of Metal-Organic Frame- works,” Sci. Rep., 4, 5443(2014).
61. Crawford, D., Casaban, J., Haydon, R., Giri, N., McNally, T. and James, S. L., “Synthesis by Extrusion: Continuous, Large-Scale Preparation of MOFs Using Little or No Solvent,” Chem. Sci., 6(3), 1645-1649(2015).
62. Gugin, N., Schwab, A., Carraro, F., Tavernaro, I., Falkenhagen, J., Villajos, J. A., Falcaro, P. and Emmerling, F., “ZIF-8-Based Bio- composites via Reactive Extrusion: Towards Industrial-Scale Manufacturing,” J. Mater. Chem. A, 14, 8728-8741(2026).
63. Valekar, A. H. and Chang, J. S., “From Metal-Organic Framework Powders to Shaped Solids: Recent Developments and Challenges,” Mater. Adv., 2(21), 7065-7086(2021).
64. Liang, W., Wied, P., Carraro, F., Sumby, C. J., Nidetzky, B., Tsung, C. K., Falcaro, P. and Doonan, C. J., “Material Design for Oral Insulin Delivery,” Med-X, 1, 6(2023).
65. Chen, Y., Li, P., Modica, J. A., Drout, R. J. and Farha, O. K., “Acid- Resistant Mesoporous Metal-Organic Framework toward Oral Insu- lin Delivery: Protein Encapsulation, Protection, and Release,” J. Am. Chem. Soc., 140(16), 5678-5681(2018).
66. Hu, X., Wang, C., Wang, L., Liu, Z., Wu, L., Zhang, G., Yu, L., Ren, X., York, P., Sun, L. and Zhang, J., “Nanoporous CD-MOF Parti- cles with Uniform and Inhalable Size for Pulmonary Delivery of Budesonide,” Int. J. Pharm., 564, 153-161(2019).
67. Kadota, K., Tse, J. Y., Fujita, S., Suzuki, N., Uchiyama, H., Tozuka, Y. and Tanaka, S., “Drug-Facilitated Crystallization of Spray-Dried CD-MOFs with Tunable Morphology, Porosity, and Dissolution Profile,” ACS Appl. Bio Mater., 6(8), 3451-3462(2023).
68. Gong, T., Zhao, K., Liu, X., Lu, L., Liu, D., Li, S. and Zhao, Y., “Dynamic Hydrogel-Metal-Organic Framework System Promotes Bone Regeneration in Periodontitis Through Controlled Drug Delivery,” J. Nanobiotechnol., 22, 299(2024).
69. Severino, M. I., Gkaniatsou, E., Nouar, F., Pinto, M. L. and Serre, C., “MOFs Industrialization: A Complete Assessment of Production Costs,” Faraday Discuss., 231, 326-341(2021).
70. Kim, J. Y., Suh, J. W., Kang, J. S., Kim, S. B., Yoon, Y. K. and Sohn, J. W., “Gram-Negative Bacteria’s Outer Membrane Vesicles,” Infect. Chemother., 55(1), 1-18(2023).
71. Li, M., Zhou, H., Yang, C., Wu, Y., Zhou, X., Liu, H. and Wang, Y., “Bacterial Outer Membrane Vesicles as a Platform for Biomedical Applications: An Update,” J. Control. Release, 323, 253-268(2020).
72. Zingl, F. G., Leitner, D. R., Thapa, H. B. and Schild, S., “Outer Mem- brane Vesicles as Versatile Tools for Therapeutic Approaches,” Microlife, 2, uqab006(2021).
73. O’Donoghue, E. J. and Krachler, A. M., “Mechanisms of Outer Membrane Vesicle Entry into Host Cells,” Cell. Microbiol., 18(11), 1508-1517(2016).
74. Guo, Q., Li, X., Zhou, W., Chu, Y., Chen, Q., Zhang, Y., Shi, J., Yu, X., Liu, X., Li, Y. and Jiang, C., “Sequentially Triggered Bacterial Outer Membrane Vesicles for Macrophage Metabolism Modulation and Tumor Metastasis Suppression,” ACS Nano, 15(8), 13826-13838(2021).
75. Meng, Y., Kong, C., Ma, Y., Sun, J. and Zhang, G., “Bacterial Outer Membrane Vesicles in the Fight Against Cancer,” Chin. Med. J., 137(18), 2169-2181(2024).
76. Chen, Z., Wang, B., Zheng, J., Liu, C., Xu, P., Zhou, Q. and Zhou, X., “Reprogramming Tumor-Associated Macrophages and Block- ing PD-L1 via Engineered Outer Membrane Vesicles to Enhance T Cell Infiltration and Cytotoxic Functions,” J. Nanobiotechnol., 23, 514(2025).
77. Kuerban, K., Gao, X., Zhang, H., Liu, J., Dong, M., Wu, L., Ye, R., Feng, M., Ye, L. and Yin, L., “Doxorubicin-Loaded Bacterial Outer-Membrane Vesicles Exert Enhanced Anti-Tumor Efficacy in Non-Small-Cell Lung Cancer,” Acta Pharm. Sin. B, 10(8), 1534-1548(2020).
78. Gujrati, V., Kim, S., Kim, S. H., Min, J. J., Choy, H. E., Kim, S. C. and Jon, S., “Bioengineered Bacterial Outer Membrane Vesicles as Cell-Specific Drug-Delivery Vehicles for Cancer Therapy,” ACS Nano, 8(2), 1525-1537(2014).
79. Gnopo, Y. M., Misra, A., Hsu, H. L., DeLisa, M. P., Daniel, S. and Putnam, D., “Induced Fusion and Aggregation of Bacterial Outer Membrane Vesicles: Experimental and Theoretical Analysis,” J. Colloid Interface Sci., 578, 522-532(2020).
80. Sepahdar, Z., Miroliaei, M., Bouzari, S., Khalaj, V. and Salimi, M., “Surface Engineering of Escherichia coli-Derived OMVs as Promis- ing Nano-Carriers to Target EGFR-Overexpressing Breast Cancer Cells,” Front. Pharmacol., 12, 719289(2021).
81. Noroozi, N., Gargari, S. L. M., Nazarian, S., Sarvary, S. and Adriani, R. R., “Immunogenicity of Enterotoxigenic Escherichia coli Outer Membrane Vesicles Encapsulated in Chitosan Nanoparticles,” Iran. J. Basic Med. Sci., 21(3), 284-291(2018).
82. Pastor, Y., Camacho, A. I., Zúñiga-Ripa, A., Merchán, A., Rosas, P., Irache, J. M. and Gamazo, C., “Towards a Subunit Vaccine from a Shigella flexneri ΔtolR Mutant,” Vaccine, 36(49), 7509-7519(2018).
83. Weynants, V., Denoel, P., Devos, N., Janssens, D., Feron, C., Goraj, K., Bos, M. P., Tommassen, J. and Poolman, J. T., “Genetically Mod- ified L3,7 and L2 Lipooligosaccharides from Neisseria menin- gitidis Serogroup B Confer a Broad Cross-Bactericidal Response,” Infect. Immun., 77(5), 2084-2093(2009).
84. Gerritzen, M. J., Maas, R. H. W., van den Ijssel, J., van Keulen, L., Martens, D. E., Wijffels, R. H. and Stork, M., “High Dissolved Oxygen Tension Triggers Outer Membrane Vesicle Formation by Neisseria meningitidis,” Microb. Cell Fact., 17, 157(2018).
85. Berlanda Scorza, F., Colucci, A. M., Maggiore, L., Sanzone, S., Rossi, O., Ferlenghi, I., Pesce, I., Caboni, M., Norais, N., Di Cioc-cio, V. and Gerke, C., “High Yield Production Process for Shigella Outer Membrane Particles,” PLoS One, 7(6), e35616(2012).
86. Klimentová, J. and Stulík, J., “Methods of Isolation and Purification of Outer Membrane Vesicles from Gram-Negative Bacteria,” Microbiol. Res., 170, 1-9(2015).
87. Kaddour, H., Tranquille, M. and Okeoma, C. M., “The Past, the Pres- ent, and the Future of the Size Exclusion Chromatography in Extra- cellular Vesicles Separation,” Viruses, 13(11), 2272(2021).
88. Chen, M. Y., Cheng, T. W., Pan, Y. C., Mou, C. Y., Chiang, Y. W., Lin, W. C. and Mou, K. Y., “Endotoxin-Free Outer Membrane Vesi- cles for Safe and Modular Anticancer Immunotherapy,” ACS Synth. Biol., 14(1), 148-160(2025).
89. Palmieri, E., Arato, V., Oldrini, D., Ricchetti, B., Aruta, M. G., Pansegrau, W., Micoli, F. and Frigimelica, E., “Stability of Outer Membrane Vesicles-Based Vaccines, Identifying the Most Appropri- ate Methods to Detect Changes in Vaccine Potency,” Vaccines, 9(3), 229(2021).
90. Studholme, L., Sutherland, J., Desai, T., Hockley, J., Care, R., Nordgren, I. K. and Collaborative Study Group, “Evaluation of the Monocyte Activation Test for the Safety Testing of Meningo- coccal B Vaccine Bexsero: A Collaborative Study,” Vaccine, 37(29), 3761-3769(2019).
91. Li, Z., Liang, D., Huo, M., Guan, L., Liu, Z., Gu, F., Guan, X. and Chen, L., “PD-L1 Nanobody-Engineered Bacterial Outer Mem- brane Vesicles Delivering Cuproptosis Micelles for Potentiated Cancer Immunotherapy,” Biomater. Adv., 180, 214552(2026).